Raymond James & Associates Boosts Stake in Henry Schein, Inc. (NASDAQ:HSIC)

Raymond James & Associates increased its stake in shares of Henry Schein, Inc. (NASDAQ:HSICGet Rating) by 94.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,153 shares of the company’s stock after buying an additional 13,709 shares during the quarter. Raymond James & Associates’ holdings in Henry Schein were worth $1,852,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in HSIC. Raymond James Financial Services Advisors Inc. increased its holdings in Henry Schein by 55.9% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 7,036 shares of the company’s stock worth $463,000 after buying an additional 2,523 shares during the period. Clarius Group LLC raised its holdings in shares of Henry Schein by 9.1% during the third quarter. Clarius Group LLC now owns 3,373 shares of the company’s stock worth $222,000 after purchasing an additional 280 shares during the last quarter. Xponance Inc. lifted its position in Henry Schein by 9.2% during the third quarter. Xponance Inc. now owns 26,984 shares of the company’s stock valued at $1,775,000 after purchasing an additional 2,271 shares during the period. Eqis Capital Management Inc. boosted its holdings in Henry Schein by 68.8% in the third quarter. Eqis Capital Management Inc. now owns 4,713 shares of the company’s stock valued at $310,000 after purchasing an additional 1,921 shares during the last quarter. Finally, Cardinal Capital Management boosted its holdings in Henry Schein by 4.5% in the third quarter. Cardinal Capital Management now owns 7,200 shares of the company’s stock valued at $474,000 after purchasing an additional 311 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Henry Schein Trading Up 0.5 %

Shares of NASDAQ:HSIC opened at $81.28 on Tuesday. The business’s 50 day moving average price is $80.72 and its 200-day moving average price is $75.62. Henry Schein, Inc. has a 1 year low of $64.75 and a 1 year high of $92.68. The firm has a market capitalization of $11.02 billion, a price-to-earnings ratio of 17.67, a price-to-earnings-growth ratio of 2.17 and a beta of 0.82. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.84 and a quick ratio of 1.00.

Henry Schein (NASDAQ:HSICGet Rating) last posted its quarterly earnings data on Tuesday, November 1st. The company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.22 billion. Henry Schein had a net margin of 5.06% and a return on equity of 15.48%. On average, equities research analysts forecast that Henry Schein, Inc. will post 4.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. William Blair reissued a “market perform” rating on shares of Henry Schein in a report on Tuesday, November 1st. Morgan Stanley lowered their price objective on Henry Schein from $72.00 to $70.00 and set an “underweight” rating on the stock in a research report on Wednesday, December 21st. Piper Sandler cut their target price on shares of Henry Schein from $96.00 to $85.00 and set an “overweight” rating for the company in a report on Monday, September 26th. Finally, StockNews.com raised shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Thursday, January 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $84.44.

Insider Buying and Selling

In other news, CEO Stanley M. Bergman sold 54,216 shares of the firm’s stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $81.16, for a total value of $4,400,170.56. Following the transaction, the chief executive officer now owns 488,126 shares in the company, valued at $39,616,306.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, SVP Lorelei Mcglynn sold 15,341 shares of the business’s stock in a transaction dated Tuesday, December 20th. The shares were sold at an average price of $80.70, for a total transaction of $1,238,018.70. Following the transaction, the senior vice president now directly owns 73,753 shares in the company, valued at $5,951,867.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stanley M. Bergman sold 54,216 shares of the stock in a transaction dated Monday, December 12th. The shares were sold at an average price of $81.16, for a total transaction of $4,400,170.56. Following the completion of the sale, the chief executive officer now owns 488,126 shares of the company’s stock, valued at approximately $39,616,306.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 76,397 shares of company stock worth $6,190,246. Insiders own 1.00% of the company’s stock.

Henry Schein Company Profile

(Get Rating)

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Featured Articles

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSICGet Rating).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.